The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer's perspective. | Glob Reg Health Technol Assess;8: 140-146, 2021. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer's perspective.

Pastor-Quirós, Luis J; Correa-Díaz, Edgar P.

Affiliation

Pastor-Quirós LJ; Independent Scholar, Heredia - Costa Rica.
Correa-Díaz EP; Neurology Department, Hospital de Especialidades Carlos Andrade Marín, Quito - Ecuador.

Glob Reg Health Technol Assess ; 8: 140-146, 2021.

Article in En | MEDLINE | ID: mdl-36627868

Key words

Alemtuzumab; Budgetary impact analysis; Fingolimod; Interferons; Multiple sclerosis; Ocrelizumab; Teriflunomide

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation Aspects: Patient_preference Country/Region as subject: America do sul / Ecuador Language: En Journal: Glob Reg Health Technol Assess Year: 2021 Document type: Article Country of publication: Italy

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation Aspects: Patient_preference Country/Region as subject: America do sul / Ecuador Language: En Journal: Glob Reg Health Technol Assess Year: 2021 Document type: Article Country of publication: Italy